Extended-Duration Short Interfering RNA Targets Hepatic Production of Apolipoprotein(a)
In a phase 1 study of 48 participants, lepodisiran reduced serum lipoprotein(a) concentrations through its actions on the production of apolipoprotein(a) in the liver. The